Open Access Research Article

Evaluation of Novel Aspirin Suppository Formulation in HT-29 Human Adenocarcinoma Cells

Miriam A Ansong*, Rocco J Rotello, Danielle Eaton, Tiffany Hong, Mallory Thompson, Sarah Meyers6, Joseph Newman, Nathanael Smith, Nicole Stute and Yang Wameng*

1-9Department of Pharmacy Practice, Cedarville University School of Pharmacy, USA

1010Department of Clinical and Administrative Sciences, California Health Sciences University, USA

Corresponding Author

Received Date:January 02, 2020;  Published Date: January 14, 2020

Abstract

Objective: The objective of this study was to evaluate a newly developed novel aspirin suppository that may have potential properties that enhance its absorption in the rectum.

Methods: This preclinical in vitro study utilized a human cell line, HT-29, to approximate the environment of the human rectum/colon. Six different suppository formulations, including zinc carnosine and acetyl salicylic acid, were used as new excipients aimed at increasing absorption of aspirin into these cells. The amount of aspirin absorbed was indirectly determined by the quantitating levels of 12(S)-HETE in pg/ml. A 12(S)-HETE competitive ELISA assay served as the primary outcome measure. Each suppository formulation was tested for its effect on cultured HT-29 cells.

Key findings: The activity measure was accomplished using light absorbance spectroscopy recorded in units of optical density (Tables 2-5). Despite some variations in the standard curve measures as described in the 12(S)-HETE kit, the authors observed absorbance of aspirin in the HT-29 cells. The results provide a platform for further preclinical studies to analyze suppository formulations in challenging in vitro models for advancing into clinical trials research.

Conclusion: Further studies utilizing a different endpoint with more specific COX-1 and possibly COX-2 assay measures and with more uniquely defined suppository mixtures may yield precise data.

Keywords: Aspirin; NPO; Suppository; Alternative

Citation
Signup for Newsletter
Scroll to Top